4.7 Article

Quinpramine is a novel compound effective in ameliorating brain autoimmune disease

Journal

EXPERIMENTAL NEUROLOGY
Volume 215, Issue 2, Pages 397-400

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2008.10.001

Keywords

-

Categories

Funding

  1. VISN 17, Department of Veterans Affairs
  2. Department of Veterans Affairs
  3. Viragh Foundation
  4. Fritz-Thyssen Foundation
  5. University of Dusseldorf

Ask authors/readers for more resources

Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and proinflammatory cytokines IFN gamma and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available